P
reeclampsia is a multisystem disorder characterized by hypertension and proteinuria occurring in the second half of pregnancy. 1 Nulliparity is a recognized risk factor. Preeclampsia carries risks of serious complications and death for the mother. 1-3 For the infant, risks include death, preterm birth, intrauterine hypoxia, and poor intrauterine growth. 1, 4, 5 The pathogenesis of preeclampsia involves inadequate trophoblast invasion, 6 often leading to poor placental perfusion; generalized endothelial dysfunction 7 ; and immune maladaptation and inflammation. 8 Oxidative stress, characterized by excessive production of reactive oxygen species, coupled with inadequate or overwhelmed antioxidant defense mechanisms, has been proposed as a link between these events.
Antioxidants are important in maintaining cellular integrity in a normal pregnancy by inhibiting peroxidation reactions and thus protecting enzymes, proteins, and cells from destruction by peroxides. Antioxidant defense mechanisms include cellular and extracellular enzymes such as glutathione reductase, superoxide dismutase, catalase, and free-radical scavengers, including vitamins C and E, carotenoids, glutathione, serum albumin, and metabolites such as bilirubin and uric acid. Vitamins C and E are antioxidants derived from the diet. Vitamin C scavenges free radicals in the aqueous phase, and the lipid-soluble vitamin E acts in vivo to prevent the formation of lipid peroxides and thus protect cell membranes.
There is evidence of oxidative stress in women with established preeclampsia, including increased plasma concentrations of 8-epi-prostaglandin F 2α , 9 lipid peroxides, 10 and decreased concentrations of antioxidants such as vitamins C and E. 11 Oxidative stress is implicated in complications affecting preterm infants, including the respiratory distress syndrome, chronic lung disease, intraventricular hemorrhage, retinopathy of prematurity, and necrotizing enterocolitis. 12,13 These observations led to the premise that prophylaxis with antioxidants may prevent oxidative stress and thereby reduce the risk of both preeclampsia in pregnant women and perinatal complications in their infants.
An initial randomized trial of prophylactic supplementation with antioxidants provided during pregnancy to 283 women at risk for preeclampsia, as compared with women not receiving antioxidant supplementation, showed a significant reduction in preeclampsia (8 percent vs. 17 percent) and a nonsignificant reduction in the risk of the infant's being small for gestational age. 14 However, a subsequent trial of antioxidants in 109 women reported no significant reduction in the risk of preeclampsia (17 percent, vs. 19 percent in the placebo group). 15 There is limited information about the effects of antioxidants on serious health outcomes in infants and on whether there may be benefits independent of a reduction in preeclampsia. There have been calls for further randomized trials in populations that have a different risk of preeclampsia to assess the efficacy and safety of antioxidant supplementation. 1, 14, 15 We designed the Australian Collaborative Trial of Supplements (ACTS) with vitamin C and vitamin E to assess whether supplementation reduced perinatal complications in nulliparous women and their infants, including preeclampsia, death, or serious outcomes, and small size for gestational age.
Me thods

STUDY DESIGN AND POPULATION
We conducted a multicenter, randomized trial involving nulliparous women with a singleton pregnancy between 14 and 22 weeks of gestation. Eligible women had normal blood pressure at the first measurement in pregnancy and again at trial entry. Women with any of the following were ineligible: known multiple pregnancy, known potentially lethal fetal anomaly, known thrombophilia, chronic renal failure, antihypertensive therapy, or specific contraindications to vitamin C or E therapy such as hemochromatosis or anticoagulant therapy. 16 The protocol was approved by the research and ethics committees at the nine collaborating hospitals. All women provided written informed consent.
Randomization was performed through a central telephone randomization service. Women assigned to the vitamin group were advised to take four coated tablets of a combination of 250 mg of vitamin C (as ascorbic acid) and 100 IU of vitamin E (as d-alpha-tocopherol succinate) each day from trial entry until they gave birth. The total daily dose of vitamin C was 1000 mg, and that of vitamin E, 400 IU. Women assigned to placebo were advised to take four tablets daily containing microcrystalline cellulose, which were similarly coated and identical in appearance to the vitamin tablets.
Women were asked to swallow the tablets whole without crushing or chewing them and were advised to take two tablets in the morning and two tablets in the evening. They were advised not to take any other antioxidant supplements, although a multivitamin preparation that provided a daily intake of no more than 200 mg of vitamin C or 50 IU of vitamin E was permitted. All infants in the study were recommended to receive intramuscular vitamin K after birth. 16 The care that the women and their infants received was according to standard practice at each center, with surveillance for hypertension with the use of standardized measurements of blood pressure. 17 Korotkoff phase V was used to measure diastolic blood pressure unless the diastolic blood pressure was 0 mm Hg, in which case Korotkoff phase IV was used. If the woman's blood pressure was elevated, urinalysis for proteinuria was recommended.
The women completed a food-frequency questionnaire at trial entry to assess dietary intake. 18 Adherence to and the side effects of treatment were assessed by self-completed questionnaires that the women answered postnatally. Women were specifically asked how often they missed taking the trial tablets and how many times a week they missed taking all the tablets. Adherence was defined by consumption of at least 80 percent of all tablets at recommended times.
OUTCOME VARIABLES
There were three primary outcomes: the development of preeclampsia in the mother, a composite measure of death or serious outcomes in the infant, and the birth of an infant who was small for gestational age. Preeclampsia was defined as hypertension (systolic blood pressure ≥140 mm Hg or diastolic blood pressure [Korotkoff V] ≥90 mm Hg on at least two occasions four or more hours apart, or both) arising after 20 weeks' gestation and one or more of the following: proteinuria, renal insufficiency, liver disease, neurologic problems, hematologic disturbances, or fetalgrowth restriction 17 (Table 1 ). The composite measure of serious outcomes in the infant was defined as one or more of the following: fetal death after trial entry (categorized as either before 20 weeks' gestation, or at 20 weeks' gestation or later); death of a live-born infant before hospital discharge; birth weight below the 3rd percentile for gestational age; severe respiratory distress syndrome (defined by a mean airway pressure of ≥10 mm Hg or a fraction of inspired oxygen of ≥0.80 cm of water, or both); chronic lung disease; intraventricular hemorrhage of grade 3 or 4; cystic periventricular leukomalacia; retinopathy of prematurity of stage 3 or 4; necrotizing enterocolitis; Apgar score of less than 4 at 5 minutes; seizures before 24 hours of age or requiring two or more drugs to control; hypotonia for at least 2 hours; stupor; decreased response to pain; coma; tube feeding for 4 or more days; care in the neonatal intensive care unit for more than 4 days; or use of ventilation for 24 hours or more. These definitions of serious outcomes are based on those used by the Australian and New Zealand Neonatal Network 19 and are important measures of morbidity at or beyond term. 20 Small size for gestational age was defined by a birth weight below the 10th percentile for gestation according to fetal sex on standardized birth-weight charts. 21 Secondary outcomes in the infants included serious complications occurring before hospital discharge. For the women, secondary outcomes included a composite of any of the following until six weeks post partum: death, pulmonary edema, eclampsia, stroke, thrombocytopenia, renal insufficiency, respiratory distress syndrome, cardiac arrest, respiratory arrest, placental abruption, abnormal liver function, preterm prelabor rupture of membranes, major postpartum hemorrhage, postpartum pyrexia, pneumonia, deep-vein thrombosis, or pulmonary embolus requiring anticoagulant therapy. Other outcomes included antenatal, intrapartum, and postnatal end points, particularly those related to hypertensive disease, including the need for antenatal hospitalization or antenatal care during the day for hypertension, need for induction of labor for hypertension, use of antihypertensive agents, and use of magnesium sulfate.
STATISTICAL ANALYSIS
Analyses were performed on an intention-to-treat basis with the use of SAS software, version 9.1. No adjustments were made, since prognostic factors were balanced at trial entry between the two groups. Relative risks with 95 percent confidence intervals are used for dichotomous variables. Continuous variables, if normally distributed, were analyzed with the use of Student's t-test, and nonparametric tests were used for skewed data. For the small number of twins (four pairs) in the study, outcomes for one randomly selected infant in each pair of twins were included in the analyses. A P value of less than 0.05 was considered to indicate statistical significance. All P values were two-sided. A step-down Sidak adjustment was made for the analyses involving multiple primary end points, with adjusted P values reported. 22 We estimated that a sample size of 1870 women would have a statistical power of 80 percent (two-tailed alpha level of 0.05) to detect a reduction in the risk of death or serious outcomes in the infants from 6.5 percent to 3.7 percent 23 (and Clinical Information Services at the Women's and Children's Hospital, Adelaide). Although our trial was powered to focus on the serious outcomes for the infant, we estimated that this sample size would also have a statistical power of 80 percent to detect a reduction in the risk of preeclampsia among the women from 10.0 percent to 6.3 percent. An interim analysis was not performed. The treatment allocation was broken after the analyses were completed. The suppliers of the tablets were not involved in any other aspect of the study including design, data management, or preparation of the manuscript.
R esults
Of the 1877 women enrolled, 935 (49.8 percent) were assigned to the vitamin group and 942 (50.2 percent) to the placebo group (Fig. 1) . Recruitment started in December 2001 and was completed in January 2005. Clinical outcomes were available up until hospital discharge for all the women who underwent randomization and their infants.
At study entry, maternal baseline characteristics in the two groups were similar, including median dietary intake of vitamins C and E (Ta- † P values were adjusted for multiple comparisons. ‡ Preeclampsia was defined as hypertension occurring with one or more of the following: proteinuria, defined as ≥300 mg of protein per 24 hours or a ratio of protein to creatinine of ≥30 mg per millimole in a "spot" urine specimen; renal insufficiency, defined by a serum or plasma creatinine level ≥0.09 mmol per liter (≥1.02 mg per deciliter) or oliguria (<30 ml of urine per hour for ≥6 hours); liver disease, defined by an aspartate aminotransferase or alanine aminotransferase level of >50 IU per liter, severe epigastric or right-upper-quadrant pain, or both; neurologic problems, defined as convulsions (eclampsia); hyperreflexia with clonus; severe headaches with hyperreflexia or persistent visual disturbances (scotomata); hematologic disturbances (thrombocytopenia, defined by a platelet count of <100,000 per cubic millimeter; disseminated intravascular coagulation, defined by an international normalized ratio of >1.5, an activated partial-thromboplastin time >5 seconds longer than the laboratory reference value, or a fibrinogen level of <1 g per liter; hemolysis, defined by a lactate dehydrogenase level >500 IU per liter, fragmentocytes on peripheral-blood smear, or both); or fetal growth restriction, defined by a birth weight below the 10th percentile for gestational age. The number of women with hypertension and one or more of the following abnormalities were as follows: proteinuria, 4.7 percent in the vitamin group and 2.8 percent in the placebo group; renal insufficiency, 1.0 percent and 0.3 percent, respectively; liver disease, 2.4 percent and 0.6 percent; neurologic problems, 1.8 percent and 1.8 percent; hematologic disturbances, 0.6 percent and 0.1 percent; and fetal growth restriction, 0.9 percent and 1. ble 2). There was no significant difference in estimated adherence between the vitamin group and the placebo group (66.6 percent vs. 69.9 percent; relative risk, 0.95; 95 percent confidence interval, 0.89 to 1.02).
PRIMARY OUTCOMES
There were no significant differences between the vitamin group and the placebo group in the risk of preeclampsia (6.0 percent and 5.0 percent, respectively; relative risk, 1.20; 95 percent confidence interval, 0.82 to 1.75), the risk of death or serious outcomes in the infants (9.5 percent and 12.1 percent; relative risk, 0.79; 95 percent confidence interval, 0.61 to 1.02), or the risk of having an infant who was small for gestational age (8.7 percent and 9.9 percent; relative risk, 0.87; 95 percent confidence interval, 0.66 to 1.16) ( Table 1) .
SECONDARY OUTCOMES
When the individual outcomes included in the composite end point of death or serious outcomes in the infants were examined, there were no significant differences for any of the outcomes between the two groups (Table 3 ). The rate of preterm birth was similar in the two groups ( Table 4) . As compared with infants in the placebo group, significantly fewer of those in the vitamin group had the respiratory distress syndrome (0.2 percent vs. 1.3 percent; relative risk, 0.17; 95 percent confidence interval, 0.04 to 0.75) and fewer required surfactant (0.2 percent vs. 1.0 percent; relative risk, 0.22; 95 percent confidence interval, 0.05 to 1.03) ( Table 4 ). There was no significant difference between the two groups of infants in the need for mechanical ventilation or the risk of other adverse outcomes, including measures of growth (Table 4) . The risk of death or serious outcomes did not differ significantly between the women in the vitamin group and those in the placebo group (10.1 percent vs. 7.7 percent; relative risk, 1.30; 95 percent confidence interval, 0.97 to 1.74) ( Table 5) . No significant differences were seen between the groups for any of the individual components of the composite maternal end point apart from a higher frequency of abnormal results on liver-function tests (raised aminotransferase levels) in the vitamin group; testing was performed only in the subgroup of women considered to have clinical indications for testing.
Women in the vitamin group had an increased risk of being admitted antenatally for hypertension and being prescribed antihypertensive drugs (Table 4 ). There were no significant differences between the two groups in the timing of detec- * Plus-minus values are means ±SD. Body-mass index is the weight in kilograms divided by the square of the height in meters. † Data are from information obtained at the first antenatal visit in the first trimester. ‡ Race or ethnic group was self-reported. § Adequate dietary intake was defined as an intake at or above the recommended daily allowances in pregnancy (vitamin C, ≥70 mg and vitamin E, ≥10 mg α-tocopherol equivalent) 24 on the basis of dietary information. ¶ Family history is based on self-reports of preeclampsia in an immediate female relative such as mother, sister, or grandmother. tion of preeclampsia, severity of disease, use of magnesium sulfate, or induction of labor because of hypertension (Table 4 ). There were also no significant differences in other antenatal, intrapartum or postnatal outcomes in self-reported side effects apart from a higher incidence of abdominal pain during late pregnancy in the vitamin group than the placebo group (7.9 percent vs. 4.8 percent; relative risk, 1.63; 95 percent confidence interval, 1.12 to 2.36).
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Discussion
In this randomized, placebo-controlled trial, giving healthy nulliparous women supplements of 1000 mg of vitamin C and 400 IU of vitamin E daily during pregnancy did not reduce their risk of preeclampsia, the risk of death or serious outcomes in their infants, or the risk of intrauterine growth restriction. This finding contrasts with the findings in an earlier trial that supplementation with vitamins C and E was beneficial in women at high risk for preeclampsia. 14 In our study, women in the vitamin group were more likely than those in the placebo group to be admitted antenatally with hypertension and to be treated with antihypertensive drugs. The cause of these unexpected adverse findings is unknown. They may be chance findings; however, such research has suggested that antioxidants may promote DNA oxidation through an interaction between vitamin C and metal ions. 25 For infants in our study, maternal vitamin supplementation was not associated with a reduc- tion in the risk of a composite end point including serious health outcomes or in the risk of intrauterine growth restriction. Although maternal supplementation was not associated with any overall benefits with respect to the primary infant outcomes, it was associated with a reduced risk of the respiratory distress syndrome and the use of surfactant. There was no significant difference in the rate of preterm birth between the two study groups. Oxidative stress has been implicated in diseases common among preterm infants, including the respiratory distress syndrome and chronic lung disease. 12,13 Maternal supplementation with antioxidant vitamins may increase the antioxidant status of at-risk infants and thus reduce the risk of diseases associated with oxidative stress, independent of any effects on preeclampsia and iatrogenic preterm birth. However, it remains possible that the isolated reductions in infant outcomes are due to chance, given that statistical adjustment was not made for multiple comparisons in the analyses of secondary outcomes. Adherence to the trial medications in our study was similar to that in other supplementation trials involving nulliparous women. 23, 26 We found no significant differences in adherence between the two groups. The doses we used are similar to those of two previous trials of supplementation with vitamins C and E. 14,15 Doses of vitamin C of 1000 mg per day, 27 which is the dose we used, result in plasma saturation. For vitamin E, doses of 400 IU per day have been shown to prevent low-density lipoprotein oxidation, 28 with limited evidence that higher doses (above 400 IU per day) are more effective. It is therefore unlikely that higher doses of these vitamins would have reduced the rate of preeclampsia.
The group receiving vitamin supplementation had a higher rate of elevated aminotransferase levels than did the placebo group. No increased risk of abnormal liver function has been reported in previous randomized trials of supplementation with vitamins C and E in pregnancy 29 or in trials of high-dose supplementation outside pregnancy. 30 In our study, liver function was assessed only in women considered to have clinical indications for testing, and therefore, the results of testing are known only for a subgroup of women. This assessment was one of multiple comparisons performed, and the results may be due to chance; other studies of supplementation with vitamins C and E in pregnancy should assess liver-function tests.
The majority of the women we studied had a baseline dietary intake of vitamins C and E above the recommended daily amount. 24 Thus, the results cannot be generalized to women with low dietary intakes of antioxidants. An ongoing trial is assessing whether antioxidants are beneficial in such women. 31 Ongoing trials are also assessing whether antioxidant supplementation is beneficial for nulliparous women 32,33 and for women considered to be at increased risk for preeclampsia, including women with diabetes 34 and those who had preeclampsia during a previous pregnancy. 31, 33, 35 Our results indicate that daily supplementation with 1000 mg of vitamin C and 400 IU of vitamin E does not reduce the risk of preeclampsia in nulliparous pregnant women or the risk of serious perinatal complications or poor intrauterine growth in their infants. Our results do not support routine supplementation with vitamins C and E during pregnancy to prevent preeclampsia or other adverse perinatal outcomes in nulliparous women.
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